Advertise on podcast: The IMID Forum

Join Professor Peter Nash from Griffith University in Brisbane and Doctor Mark Gibson from the Centre for Rheumatic Diseases, King’s College London, as they discuss Doctor Gibson’s recent paper, ‘Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs’.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review paper by Bechman et al. where he highlights the impact of BMI on response to JAK inhibitors in RA.

Join Dr Sofia Ramiro and Dr Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered whether men and women with axSpA respond differently to bimekizumab, using 52-week data from the BE MOBILE 1 and 2 trials, covering both non-radiographic and radiographic axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor van Mulligen, from the Department of Rheumatology, Leiden University Medical Centre, as they discuss her recent paper ‘Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibodynegative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Finckh et al. and Charles‑Schoeman et al, in which authors the impact of shared epitope positivity on bDMARD effectiveness and compare treatment persistence and switching to UPA versus other advanced therapies after TNFi failure.

Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in PsA. This month’s conversation explores recent advances in PsA and immune-mediated inflammatory disease therapies.

Join Professor Peter Nash from the Griffith University in Brisbane; Professor Axel Finckh, from the Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland; and Bente Glintborg, an Associate Professor from the Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark as they discuss his recent paper ‘Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis’.

Join Professor Iain McInnes and Doctor Philip Mease for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they examine key findings from studies by Fleischmann et al. and Nozaki et al. discussing the long-term effectiveness and safety of advanced targeted therapies for RA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Laura Coates, Professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, as they discuss a recent paper ‘Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: Results from a randomized clinical trial’.

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Murat Torgutalp, from the Charité – Universitätsmedizin in Berlin, as they discuss his recent paper ‘Frequency and characteristics of axial involvement in psoriatic arthritis: Results from the International Multicentre AXIS Study’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two recent studies by Etani et al. and George et al. that examine the infectious complications associated with immunosuppressive therapy in rheumatoid arthritis, including herpes zoster risk across five JAK inhibitors and the relationship between RA treatments and nonserious infections.